10-Q - TELA Bio, Inc. (0001561921) (Filer)

8-K - TELA Bio, Inc. (0001561921) (Filer)

SCHEDULE 13G/A - TELA Bio, Inc. (0001561921) (Subject)

SCHEDULE 13G/A - TELA Bio, Inc. (0001561921) (Subject)

DEFA14A - TELA Bio, Inc. (0001561921) (Filer)

DEF 14A - TELA Bio, Inc. (0001561921) (Filer)

PRE 14A - TELA Bio, Inc. (0001561921) (Filer)

8-K - TELA Bio, Inc. (0001561921) (Filer)

S-8 - TELA Bio, Inc. (0001561921) (Filer)

10-K - TELA Bio, Inc. (0001561921) (Filer)

Piper Sandler downgraded TELA Bio from Overweight to Neutral and set a new price target of $2.00 from $5.00 previously

Lake Street initiated coverage of TELA Bio with a rating of Buy and set a new price target of $17.00

MALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Delivered revenue of $18.5 million in the first quarter 2025, representing growth of 12% over the prior year period and sequential growth of 5% over the fourth quarter of 2024;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the first quarter, resulting in year-over-year revenue increase for each product of approximately 15% and 2%, respectively;Commenced full U.S. comme

MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial results on Thursday, May 8, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the

MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered revenue of $17.6 million in the fourth quarter and $69.3 million for the full year 2024, representing growth of 4% and 19%, respectively, over the corresponding periods of 2023;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the full year 2024, resulting in growth in unit sales volume for each product of approximately 33% and 31%, r

MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 20, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Fourth Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15

MALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2024 financial results on Thursday, November 7, 2024. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Third Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before

MALVERN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Reported revenue of $16.1 million in the second quarter, representing growth of 11% over the prior year period of 2023;Appointed Greg Firestone as Chief Commercial Officer on May 20, 2024 to drive our next phase of revenue growth by enhancing sales representative training, regional supervision, and performance measurement and accountability;Launched our robotically compatible OviTex IHR Reinforced Tiss

MALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2024 financial results on Monday, August 12, 2024. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Second Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before

MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Reported revenue of $16.6 million in the first quarter, representing growth of 39% over the prior year period of 2023;Delivered the 13th consecutive quarter of at least 35% year-over-year growth;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the first quarter, resulting in a year-over-year revenue increase for each product of approximately 31% and 54%, respectively;Appo

MALVERN, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2024 financial results on Thursday, May 9, 2024. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the

MALVERN, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today reported financial results for the fourth quarter and full year ended December 31, 2023. Recent Highlights Reported revenue of $17.0 million in the fourth quarter and $58.5 million for the full year 2023, representing growth of 46% and 41%, respectively, over the corresponding periods of 2022;Delivered the 12th consecutive quarter and third consecutive year of at least 35% year-over-

MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 6,600 shares of its common stock to twelve newly-hired employees, with a grant date of May 5, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her ac

MALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Delivered revenue of $18.5 million in the first quarter 2025, representing growth of 12% over the prior year period and sequential growth of 5% over the fourth quarter of 2024;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the first quarter, resulting in year-over-year revenue increase for each product of approximately 15% and 2%, respectively;Commenced full U.S. comme

MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial results on Thursday, May 8, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the

MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on advancing soft-tissue reconstruction solutions, today announced the U.S. launch of larger sizes of OviTex PRS Reinforced Tissue Matrix, the only tissue-based device reinforced with polymer suture embroidery specifically engineered for plastic and reconstructive surgery. Designed for consistency in thickness, stretch, permeability, and handling while facilitating functional remodeling,1 the OviTex PRS portfolio now includes expanded size offerings, including a 25 x 30 cm oval and a 25 cm diameter circle. These larger configurations may reduce the need fo

MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered revenue of $17.6 million in the fourth quarter and $69.3 million for the full year 2024, representing growth of 4% and 19%, respectively, over the corresponding periods of 2023;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the full year 2024, resulting in growth in unit sales volume for each product of approximately 33% and 31%, r

MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 20, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Fourth Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15

MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 7,200 shares of its common stock to thirteen newly-hired employees, with a grant date of February 19, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his

MALVERN, Pa., Jan. 24, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 4,000 shares of its common stock to seven newly-hired employees, with a grant date of January 21, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or h

MALVERN, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 1,700 shares of its common stock to three newly-hired employees, with a grant date of December 11, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or

MALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler's 36th Annual Healthcare Conference. TELA's management is scheduled to present at Piper Sandler's 36th Annual Healthcare Conference at 12:00 pm ET on December 3rd, 2024. Interested parties can access the live and archived webcast at ir.telabio.com. About TELA Bio, Inc.TELA Bio, Inc. (NASDAQ:TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by

MALVERN, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment, to its Board of Directors, effective June 4, 2024. "We are excited to have Jeff join our Board as we continue to develop and optimize our sales force," said Antony Koblish, co-founder, President and Chief Executive Officer of TELA Bio. "Jeff's exceptional sales leader

MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Greg Firestone as the Company's new Chief Commercial Officer. In this role, Mr. Firestone will oversee the Company's commercial operations, including key product launches, sales team training, market development, as well as strategic initiatives to optimize market access and reimbursement strategy across the Company's product lines. "Greg has been an instrumental player in the TELA Bio story, supporting our commercial strategy and cultivating each of our key group

MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced Howard N. Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strategy. Dr. Langstein is the former Chief of Plastic and Reconstructive Surgery at the University of Rochester Medical Center, known for his extensive expertise, especially in microvascular reconstruction and innovative approaches to complex surgical problems. Dr. Langstein previously held the position of Associate Professor of Plastic Surgery at the University of Texas MD Anderson Cancer Center, where

MALVERN, Pa., April 18, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced the hiring of D. Taylor Ocasio as the Company's new General Counsel (GC). As GC, Mr. Ocasio will lead the Company's legal and governance efforts. Mr. Ocasio joins TELA with nearly ten years of corporate legal operations and healthcare industry experience. Most recently, Mr. Ocasio served as Deputy General Counsel of Zynerba Pharmaceuticals, a clinical-stage specialty pharmaceuti

MALVERN, Pa., Sept. 27, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced the appointment of Roberto Cuca as the Company's new Chief Operating Officer (COO) and Chief Financial Officer (CFO). As COO and CFO, Roberto Cuca will lead the execution of the Company's business plan and manage the Company's finances. He will report directly to President and Chief Executive Officer, Antony Koblish. Roberto Cuca joins the TELA team with over 25 years of experience in relevant operational and fina

MALVERN, Pa., June 02, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that it has appointed John Nosenzo, the Chief Commercial Officer of Bioventus Inc., to its board of directors effective June 2, 2021. Concurrent with the appointment of John Nosenzo, as previously announced, our current board member Adele Olivia will be stepping down. Following these changes, TELA Bio's board will be composed of seven directors, six of whom are independent. "I am very excited to welcome John t

MALVERN, Pa., May 25, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced the appointment of Marissa Conrad as the company's Vice President of Clinical and Regulatory Affairs effective May 24, 2021. As Vice President of Clinical and Regulatory Affairs, Marissa will establish and execute the clinical and regulatory strategy for TELA Bio's current products and future product pipeline. Marissa brings over 16 years of R&D, clinical, and regulatory experience in the medtech industry to TELA Bio, inc

Bruce Freedman, M.D. joins innovative MedTech company to advocate for more natural surgical hernia mesh options MALVERN, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), an innovative MedTech company focused on advancing the field of soft-tissue reconstruction, announced today that it has welcomed Bruce Freedman, M.D., FACS as Vice President of Clinical Development. After 32 years as a private practice general surgeon specializing in hernia repair and abdominal wall reconstruction, Dr. Freedman has joined TELA Bio to advocate for a more natural hernia repair mesh option as an alternative to permanent and resorbable synthetic mesh. “As a surgeon who has perfo